There are 2 listed Contraceptives/Protectives stocks in India: Cupid (₹48,838 crore) and Anondita Medicare (₹2,018 crore), at prices of 18 November 2026. 1 of the 2 companies we track is beating the Nifty 500 on share price over recent months.
Contraceptives/Protectives: Cupid Ltd owns the largest revenue base AND the fastest current growth.
The main question: the lead sits with a few companies, so how long it lasts matters more than the rank.
Start with size. Then the direction of earnings. Then the quality of the business. A share price that leads means more once those three agree.
How big is the Contraceptives/Protectives sector?
There are 2 listed Contraceptives/Protectives companies on this page, worth ₹50,900 cr together at prices of 18 November 2026. Cupid alone is ₹48,800 cr, about 96% of the total.
Market values at prices of 18 November 2026.
What did Contraceptives/Protectives managements say about July to September 2026?
1 of 2 Contraceptives/Protectives companies held a results call for July to September 2026. Anondita Medicare guided: FY27 revenue ₹240 crore to ₹250 crore.
Anondita Medicare call 16 November 2026
“We would proudly say that we are the only company in the world that manufactures male latex, male non-latex, female latex, and female non-latex condoms.”Anupam Ghosh
Guided: FY27 revenue ₹240 crore to ₹250 crore.
From the results calls for July to September 2026.
Which are the biggest Contraceptives/Protectives stocks in India?
The largest Contraceptives/Protectives stocks in India by market value are Cupid (₹48,838 crore) and Anondita Medicare (₹2,018 crore), at prices of 18 Nov 2026.
- Cupid: ₹363.20 | market value ₹48,838 crore | P/E 277.2
- Anondita Medicare: ₹1,059.30 | market value ₹2,018 crore | P/E 60.1
Share price | market value | P/E, biggest first. Prices, market values and ratios at the official close of 18 Nov 2026; the score list below uses the weekly figures.
Is there a Nifty Contraceptives/Protectives index, and what is in it?
All 2 listed Indian Contraceptives/Protectives companies are named here, largest first. This is the set of companies people mean when they search for a Nifty Contraceptives/Protectives index; the exchange publishes its own indices only for the largest sectors, so this equal-weighted set stands in for one. Every figure is equal-weighted across those companies and carries its own as-of date.
- Cupid Ltd₹48,800 cr
- Anondita Medicare Ltd₹2,020 cr
How many Contraceptives/Protectives companies are listed in India?
2 Contraceptives/Protectives companies in the Contraceptives/Protectives industry group have a page on Sector Alpha, and all 2 are listed below, largest first. The largest is Cupid (₹48,838 crore) and the smallest with a market value is Anondita Medicare.
| Company | Market value |
|---|---|
| 1. Cupid Ltd CUPID | ₹48,838 crore |
| 2. Anondita Medicare Ltd ANONDITA | ₹2,018 crore |
Is Contraceptives/Protectives outperforming NIFTY 500?
Contraceptives/Protectives has done better than the NIFTY 500 by 287.8% over the last 52 weeks. Over 13 weeks the gap is a lead of 11%. Cupid Ltd is the strongest against the sector itself at +39.4%. Readings are as of 13 November 2026.
Relative-strength score for the industry: 27.8 as of 13 November 2026 (consolidation, falling).
What is the bottom line on Contraceptives/Protectives?
Contraceptives/Protectives has done better than the NIFTY 500 by 287.8% over 52 weeks and by 11% over 13 weeks. 1 of 2 companies we track is beating the NIFTY on relative strength (how a share price has done against the index over recent months). Cupid Ltd has the fastest current revenue growth at 100%, across 1 of 2 comparable companies.
How does each Contraceptives/Protectives stock score?
A score that ranks each company against the others in its industry. The four parts shown always add up to the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or old evidence affects only its own part, never as a hidden adjustment.
Cupid Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 80% evidence confidence.
- 1Cupid LtdCUPID · leader · favourable · 80% evidence79.0out of 100
How the score adds up
Growth & earnings 28.0/35 · Revenue 100% · PAT 100% · OPM change −5 pp · 100% evidenceCapital efficiency 21.0/25 · ROCE 33.9% (year to Mar 2026) · OPM 29.3% · 100% evidenceValuation 10.0/20 · P/E 288.3× · PEG — · 0% evidenceRelative strength 20.0/20 · RS sector 39.4% · RS bench 112.7% · 1Y 439.1% · 100% evidence · 12 of 12 weeks aheadExact sum: 28 + 21 + 10 + 20 = 79 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
Ranked last: too little evidence (1 company)
Under 60% of the evidence behind this score is available, so it ranks after every company above, whatever the score.
- 2Anondita Medicare LtdANONDITA · quiet · provisional · 28% evidence59.4out of 100
How the score adds up
Growth & earnings 17.6/35 · Revenue — · PAT — · OPM change 3 pp · 15% evidenceCapital efficiency 19.3/25 · ROCE 43.8% (year to Mar 2026) · OPM 37.4% · 71% evidenceValuation 10.0/20 · P/E 60.3× · PEG — · 0% evidenceRelative strength 12.5/20 · RS sector — · RS bench 8.2% · 1Y 70.4% · 25% evidence · 0 of 12 weeks aheadExact sum: 17.6 + 19.3 + 10 + 12.5 = 59.4 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
How this score is built, and what the marks mean
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
How have Contraceptives/Protectives share prices moved?
Cupid Ltd has the strongest one-year price move in Contraceptives/Protectives at +439.1%. It also leads on relative strength against the NIFTY, at +112.7%. 2 of 2 companies we track are ahead of the index on that measure. Every line covers 314 weekly closes through 13 November 2026.
Price and relative strength
Price · same starting point: Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts: the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
RS vs NIFTY 500: How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
RS vs sector: The same measure taken against Contraceptives/Protectives itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
Biggest one-year moves
- 1Cupid LtdCUPID · ₹48,800 cr+439.1%1 year
- 2Anondita Medicare LtdANONDITA · ₹2,020 cr+70.4%1 year
Strongest against NIFTY 500
- 1Cupid LtdCUPID · ₹48,800 cr+112.7%vs NIFTY 500
- 2Anondita Medicare LtdANONDITA · ₹2,020 cr+8.2%vs NIFTY 500
Strongest against the sector itself
- 1Cupid LtdCUPID · ₹48,800 cr+39.4%vs sector
Which Contraceptives/Protectives companies have the most revenue, and which grow fastest?
Cupid Ltd has the highest Revenue among the 2 Contraceptives/Protectives companies compared here, at ₹557 crore. The same company also has the highest Revenue growth, at the 100% top of the scoring scale. 1 of 2 companies report a comparable reading, the latest through Sep 2026. Its Revenue series carries 20 reported observations across the 20-quarter window.
What the numbers say: Cupid Ltd is the largest at ₹557 crore, Cupid Ltd's growth is capped at 100% on the scoring scale; the full change over the last 12 months is 126.4% from a ₹557 crore base, with 20 reported quarters out of the last 20. Fast growth from a smaller base is not yet the same as proven size.
What this means: Cupid Ltd is both the largest and the fastest-growing company here; the growth has to turn into margin and returns before it counts as more than a fast start.
This conclusion weakens if: Cupid Ltd's revenue growth slows for two consecutive comparable reports while its operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenue · company comparison
Revenue · largest
- 1Cupid LtdCUPID₹557 cr
Revenue growth · fastest growers
- 1Cupid LtdCUPID100%
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Cupid Ltd CUPID | ₹188 cr | 124% | Sep 2026 |
| Anondita Medicare Ltd ANONDITA | ₹83 cr | 80% | Mar 2026 |
Revenue shows both size and speed. A large company can absorb shocks and pay for wide distribution; faster growth can mean market-share gains, new capacity or stronger demand. The best sign is usually growth that lasts without hurting margins and returns.
What to watch
Watch the next two reported quarters for growth persistence, margin conversion and whether the leader is gaining share without stretching working capital.
Which Contraceptives/Protectives companies keep the most from each ₹100 of sales?
Anondita Medicare Ltd has the highest OPM among the 2 Contraceptives/Protectives companies compared here, at 37.4%. Cupid Ltd is next at 29.3%. The same company also has the highest Margin change, at +3 percentage points. 2 of 2 companies report a comparable reading, the latest through Mar 2026. Its OPM series carries 4 reported observations across the 20-quarter window.
What the numbers say: Anondita Medicare Ltd leads both opm at 37.4% and margin change at +3 percentage points.
What this means: Anondita Medicare Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
Operating margin · company comparison
OPM, by reported quarter
- Anondita Medicare 38%
- Cupid 29%
| Quarter | Anondita Medicare | Cupid |
|---|---|---|
| Dec 2021 | — | 12% |
| Mar 2022 | — | 18% |
| Jun 2022 | — | 17% |
| Sep 2022 | — | 25% |
| Dec 2022 | — | 33% |
| Mar 2023 | — | 26% |
| Jun 2023 | — | 9.0% |
| Sep 2023 | — | 20% |
| Dec 2023 | — | 30% |
| Mar 2024 | — | 49% |
| Jun 2024 | — | 17% |
| Sep 2024 | 31% | 25% |
| Dec 2024 | — | 25% |
| Mar 2025 | 35% | 24% |
| Jun 2025 | — | 28% |
| Sep 2025 | 35% | 34% |
| Dec 2025 | — | 37% |
| Mar 2026 | 38% | 31% |
| Jun 2026 | — | 39% |
| Sep 2026 | — | 29% |
Margin change, by reported quarter
- Anondita Medicare +3.0 pp
- Cupid −5.0 pp
| Quarter | Anondita Medicare | Cupid |
|---|---|---|
| Dec 2021 | — | −15.8 pp |
| Mar 2022 | — | −3.7 pp |
| Jun 2022 | — | −8.3 pp |
| Sep 2022 | — | +5.0 pp |
| Dec 2022 | — | +21.0 pp |
| Mar 2023 | — | +7.7 pp |
| Jun 2023 | — | −7.7 pp |
| Sep 2023 | — | −5.0 pp |
| Dec 2023 | — | −3.0 pp |
| Mar 2024 | — | +23.0 pp |
| Jun 2024 | — | +8.0 pp |
| Sep 2024 | — | +5.0 pp |
| Dec 2024 | — | −5.0 pp |
| Mar 2025 | — | −25.0 pp |
| Jun 2025 | — | +11.0 pp |
| Sep 2025 | +4.0 pp | +9.0 pp |
| Dec 2025 | — | +12.0 pp |
| Mar 2026 | +3.0 pp | +7.0 pp |
| Jun 2026 | — | +11.0 pp |
| Sep 2026 | — | −5.0 pp |
2 of 2 companies report OPM, 2 of 2 margin change.
OPM · highest
- 1Anondita Medicare LtdANONDITA · older report37%
- 2Cupid LtdCUPID29%
Margin change · fastest expanders
- 1Anondita Medicare LtdANONDITA · older report+3.0 pp
- 2Cupid LtdCUPID−5.0 pp
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Anondita Medicare Ltd ANONDITA | 38% | +3.0 pp | Mar 2026 |
| Cupid Ltd CUPID | 29% | −5.0 pp | Sep 2026 |
What to watch
Watch whether the next two comparable periods confirm the current margin change rather than reversing it.
Which Contraceptives/Protectives companies earn the most profit?
Cupid Ltd has the highest Net profit among the 2 Contraceptives/Protectives companies compared here, at ₹169 crore. The same company also has the highest Profit growth, at the 100% top of the scoring scale. 1 of 2 companies report a comparable reading, the latest through Sep 2026. Its Net profit series carries 20 reported observations across the 20-quarter window.
What the numbers say: Cupid Ltd earns the most, ₹169 crore of profit over the last 12 months, Cupid Ltd shows at least 100% on the scoring scale (172.6% in full) growth from a profit base of ₹169 crore. A fast rate from a small base matters less than a large profit that keeps coming.
What this means: Cupid Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profit · company comparison
Net profit · largest
- 1Cupid LtdCUPID₹169 cr
Profit growth · fastest growers
- 1Cupid LtdCUPID100%
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Cupid Ltd CUPID | ₹56 cr | 133% | Sep 2026 |
| Anondita Medicare Ltd ANONDITA | ₹21 cr | 110% | Mar 2026 |
What to watch
Watch whether the next two comparable periods confirm the current profit growth rather than reversing it.
Which Contraceptives/Protectives companies earn the best return on capital?
Anondita Medicare Ltd has the highest ROCE among the 2 Contraceptives/Protectives companies compared here, at 43.8%. Cupid Ltd is next at 33.9%. Cupid Ltd has the highest ROCE change at +16.4 percentage points, so level and change sit with different companies. 2 of 2 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Anondita Medicare Ltd leads ROCE at 43.8%, 9.9 percentage points above Cupid Ltd. A high return reported once may be one good year; a high return reported year after year shows a lasting business.
What this means: Anondita Medicare Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
Return on capital · company comparison
ROCE · highest
- 1Anondita Medicare LtdANONDITA · older report44%
- 2Cupid LtdCUPID34%
ROCE change · fastest improvers
- 1Cupid LtdCUPID+16.4 pp
- 2Anondita Medicare LtdANONDITA · older report−18.0 pp
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Cupid Ltd CUPID | 33% | +16.4 pp | Sep 2026 |
| Anondita Medicare Ltd ANONDITA | 32% | — | Mar 2026 |
What to watch
Watch whether the next two comparable periods confirm the current roce change rather than reversing it.
How are Contraceptives/Protectives stocks valued against growth and quality?
No company in this Contraceptives/Protectives comparison reports a valuation figure this section can compare, so the PEG rank is empty. On P/E, Anondita Medicare Ltd is lowest at 60.3× at the latest share price, across 2 of 2 companies with a usable reading.
What the numbers say: There is not enough comparable evidence to name a reliable peg leader.
What this means: A low valuation is a reason to look closer at the business, not a conclusion on its own.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is worked out the same way every time, as the P/E on the last 12 months of reported earnings divided by that growth rate, never on expected earnings. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
Valuation · company comparison
PEG, by reported quarter
| Quarter | Cupid |
|---|---|
| Dec 2021 | — |
| Mar 2022 | — |
| Jun 2022 | — |
| Sep 2022 | — |
| Dec 2022 | — |
| Mar 2023 | — |
| Jun 2023 | — |
| Sep 2023 | — |
| Dec 2023 | 2.6 |
| Mar 2024 | — |
| Jun 2024 | — |
| Sep 2024 | 1.0 |
| Dec 2024 | — |
| Mar 2025 | — |
| Jun 2025 | — |
| Sep 2025 | — |
| Dec 2025 | — |
| Mar 2026 | — |
| Jun 2026 | — |
| Sep 2026 | — |
P/E, by reported quarter
- Cupid 258.3×
- Anondita Medicare 75.1×
| Quarter | Cupid | Anondita Medicare |
|---|---|---|
| Dec 2021 | 10.3× | — |
| Mar 2022 | 16.3× | — |
| Jun 2022 | 14.6× | — |
| Sep 2022 | 16.3× | — |
| Dec 2022 | 19.1× | — |
| Mar 2023 | 17.6× | — |
| Jun 2023 | 17.5× | — |
| Sep 2023 | 28.4× | — |
| Dec 2023 | 77.9× | — |
| Mar 2024 | 112.2× | — |
| Jun 2024 | 61.3× | — |
| Sep 2024 | 56.0× | — |
| Dec 2024 | 40.8× | — |
| Mar 2025 | 33.1× | — |
| Jun 2025 | 72.1× | — |
| Sep 2025 | 139.6× | 40.4× |
| Dec 2025 | 310.6× | — |
| Mar 2026 | 136.3× | 75.1× |
| Jun 2026 | 226.9× | — |
| Sep 2026 | 258.3× | — |
0 of 2 companies report PEG, 2 of 2 P/E.
PEG · lowest PEG
Not enough comparable data.
P/E · lowest P/E
- 1Anondita Medicare LtdANONDITA · older report60.3×
- 2Cupid LtdCUPID288.3×
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| Cupid Ltd CUPID | 1.0 | 258.3× | Sep 2026 |
| Anondita Medicare Ltd ANONDITA | — | 75.1× | Mar 2026 |
What to watch
Watch whether the next two comparable periods confirm the current p/e rather than reversing it.
Which stock lists do Contraceptives/Protectives companies appear on?
Contraceptives/Protectives companies show up on 3 of our India lists. The most are on the momentum stocks list (1 company).
What can make this comparison misleading?
This Contraceptives/Protectives comparison names 6 specific ways its own evidence can mislead, all listed below. 1 of the 2 companies reports on an older date than the sector's freshest reporters, so its rank is marked stale. 3 of the 5 ranked sections have fewer than three usable current readings.
Keep these limits visible
- A high growth rate can come from a very small starting figure. The page keeps level and change separate for that reason.
- A high ROCE can be temporary, or look high because the capital base is small. It is best read beside margin, cash flow and how much is spent back on the business.
- The 4-Factor Sector Score ranks published data only. Management quality, upcoming events and risks are not part of it.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 1 company has an older fundamental reporting date than the sector’s freshest reporters; its rank carries a stale marker.
- Thin comparisons: Revenue, Net profit, Valuation have fewer than three usable current readings.
How was this comparison built?
This comparison is built from the reported filings of 2 Contraceptives/Protectives companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Sep 2026 and market data through 13 November 2026.
Every company's second-feed figures reconcile against the primary source on overlapping reported periods, so nothing here is unverified or withheld.
How a second data feed is admitted, and what happens when it disagrees
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree, the figures are simply used. Where there is too little shared history to compare, the figures are still drawn, they are the only evidence there is, and marked unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.
What else do people ask about Contraceptives/Protectives stocks?
These 21 answers restate the Contraceptives/Protectives comparison above in question form. Every one is computed from the same 2 companies and the same reported filings as the rankings and charts, current through Sep 2026. Price and relative-strength answers run through 13 November 2026. Nothing here is estimated, and none of it is a recommendation.
Is the Contraceptives/Protectives sector outperforming NIFTY 500?
Contraceptives/Protectives has done better than the NIFTY 500 by 287.8% over 52 weeks and by 11% over 13 weeks. 1 of 2 companies we track is beating the NIFTY on relative strength (how a share price has done against the index over recent months).
Which Contraceptives/Protectives company is largest by revenue?
Cupid Ltd leads with revenue of ₹557 crore, based on 1 of 2 comparable companies through Sep 2026.
Which Contraceptives/Protectives company is growing fastest?
Cupid Ltd has the fastest current revenue growth at 100%, across 1 of 2 comparable companies.
Which Contraceptives/Protectives company has the strongest 4-Factor Sector Score?
Cupid Ltd ranks first at 79 out of 100, with 80% of the evidence available. The score ranks published data; it is not a recommendation.
How much history does this Contraceptives/Protectives comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Sep 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four parts add up directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or old evidence moves only that part toward the middle.
Is there a Nifty Contraceptives/Protectives index?
The exchange runs Nifty indices for several broad sectors, such as Nifty Bank, Nifty IT and Nifty Pharma, but not for every smaller group on this site.
Whether or not an official Nifty index covers Contraceptives/Protectives, this page builds its own equal-weight basket of 2 listed Contraceptives/Protectives companies: one company, one vote, whatever its size, so no single large company dominates. Figures are as of Sep 2026.
Which are the best Contraceptives/Protectives stocks in India?
Ranked by this page's four-factor score, Cupid Ltd comes first among 2 listed Contraceptives/Protectives companies, followed by Anondita Medicare Ltd. That is a ranking of published data (earnings, quality, valuation and share-price behaviour as of Sep 2026), not a recommendation.
How many Contraceptives/Protectives stocks are listed in India?
This comparison covers 2 listed Contraceptives/Protectives companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Sep 2026.
Which Contraceptives/Protectives company is the biggest?
Cupid Ltd is the largest, with revenue of ₹557 crore over the last 12 months. That covers 1 of 2 companies with comparable reporting through Sep 2026.
Which Contraceptives/Protectives company has the best profit margins?
Anondita Medicare Ltd has the highest operating margin at 37.4%, from 2 of 2 comparable companies. Anondita Medicare Ltd shows the biggest recent improvement, at +3 percentage points. A high margin matters most when it is steady or rising, not when it is at a peak.
Which Contraceptives/Protectives company makes the most profit?
Cupid Ltd earns the most, at ₹169 crore of net profit over the last 12 months, from 1 of 2 comparable companies.
Cupid Ltd has the fastest profit growth at the 100% cap of the scoring scale, though growth off a small or recovering profit base overstates how much has actually changed.
Which Contraceptives/Protectives company earns the highest return on capital?
Anondita Medicare Ltd leads on return on capital employed at 43.8%, across 2 of 2 companies. A high return that repeats for years shows a lasting business, while a single high reading can come from a small capital base or one good year.
Is the Contraceptives/Protectives sector beating the market?
Contraceptives/Protectives has done better than the NIFTY 500 by 287.8% over the last 52 weeks and by 11% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 1 of the 2 companies we track is beating the market on their own.
Sector strength does not transfer evenly to every stock in it.
Which Contraceptives/Protectives stock has the strongest price momentum?
Cupid Ltd has the strongest relative strength against the NIFTY 500, meaning its share price has done best against the index. A price can move well before the business results back it up, and sometimes without them.
Which Contraceptives/Protectives company has the highest 4-Factor score?
Cupid Ltd scores 79 out of 100, with 80% of the evidence available, from 28 points on growth and earnings, 21 on capital efficiency, 10 on valuation and 20 on relative strength. It ranks published data only; management quality, upcoming events and risks are not part of the score.
How many Contraceptives/Protectives companies does this comparison cover, and over what period?
This comparison covers 2 listed companies over up to 20 reported quarters of fundamentals, ending Sep 2026, plus weekly price and relative-strength history. Membership is the full sector list, nothing is dropped for having thin data.
What is the total market cap of the Contraceptives/Protectives sector?
The 2 Contraceptives/Protectives companies on this page carry ₹50,855 crore of combined market value. Cupid Ltd is the largest at ₹48,838 crore, about 96% of the sector's total on its own. Market value moves with price, so this reading is dated 13 November 2026.
How is the Contraceptives/Protectives sector performing?
1 of the 2 Contraceptives/Protectives companies we track is doing better than the NIFTY 500 on relative strength (how a share price has done against the index over recent months). The sector itself is 287.8% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members.
Readings are as of 13 November 2026.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing figures are never estimated, copied forward or swapped for a similar-looking line, and a company with missing evidence has its score pulled toward the middle rather than scored as bad.
Is this advice?
No, every figure here is worked out by code from company filings and market data, for research. It does not account for your situation and is not a substitute for advice from a registered adviser.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
Every India sector against its index · What changed this week · Plain-text data
Sector Alpha, written by code from the published numbers · Fundamentals through Sep 2026 · Prices through 13 November 2026. Every ranking is worked out by code from reported figures. Missing values stay missing.
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.